Experts from the Society of Nuclear Medicine and Molecular Imaging will speak on the most advanced nuclear medicine technology in both the imaging and therapy of prostate cancer. Prostate specific membrane antigen (PSMA) has been extensively studied as both an imaging and therapeutic target for prostate cancer and therefore also as a theranostic target. PSMA-targeted radiopharmaceuticals for PET imaging and for delivery of therapeutic radiation are now in phase 3 trials and thus may soon be available to greatly expand the role of nuclear medicine in the care of patients with prostate cancer.

Learning Outcomes and Modules  

After completing this course, the learner should be able to:

– describe the capabilities of PSMA-PET imaging for prostate cancer

– discuss PSMA targeted PET interpretation

– discuss clinical indications for ordering of fluciclovine-PET

Lectures

– Mastering the Interpretation of Fluciclovine-PET—S. Galgano

– PSMA-targeted PET Imaging for Prostate Cancer—K. Zukotynski

– Theranostics for Prostate Cancer—P. Kuo

Date of issuance: June 5, 2020
Date of expiration: June 4, 2023